Reconsidering complete response and delayed nephrectomy in mRCC: a call for precision in defining outcomes

Affiliations

¹ Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey. drmutlucatli@hotmail.com.
² Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.

Comment

Mehmet Mutlu Çatlı et al. World J Urol. 2025.

. 2025 May 4;43(1):265.

doi: 10.1007/s00345-025-05525-4.

¹ Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey. drmutlucatli@hotmail.com.
² Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey.

No abstract available

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, Borchiellini D, Bensalah K, Schlürmann F, Ladoire S, Parier B, Bernhard JC, Cassuto O, Albigès L, Thibault C, Ingels A, Cherifi F, Waeckel T, Flippot R, Geoffrois L, Walz J, Gravis G, Barthélémy P. Pignot G, et al. World J Urol. 2025 Jan 2;43(1):54. doi: 10.1007/s00345-024-05361-y. World J Urol. 2025. PMID: 39747746

1. Pignot G, Galy A, Bigot P, et al (2024) The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma. World J Urol doi:10.1007/s00345-024-05361-y
1. Motzer RJ, Tannir NM, McDermott DF, et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. doi:10.1056/NEJMoa1712126
1. Rini BI, Plimack ER, Stus V, et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 380(12):1116–1127. doi:10.1056/NEJMoa1816714
1. Sharma P, Hammers HJ, Escudier B, et al (2020) Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for treatment-naive advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups: a post hoc analysis of CheckMate 214. Eur Urol Oncol 3(3):372–382. doi:10.1016/j.euo.2020.03.007
1. Atkins MB, Plimack ER, Puzanov I, et al (2022) Pembrolizumab plus axitinib in patients with advanced renal cell carcinoma: updated follow-up of efficacy and safety from KEYNOTE-426. Eur Urol 82(4):417–428. doi:10.1016/j.eururo.2022.05.019